Previous guidance was $8.45-$8.85. “As compared to our February guidance, our updated full year 2026 GAAP and non-GAAP diluted earnings per share guidance was reduced by approximately $9.50 due to the anticipated acquired IPR&D charges of $11.5 billion as well as financing costs related to the Arcellx, Inc, Ouro Medicines, LLC, and Tubulis GmbH transactions.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- These Are the Stocks Reporting Earnings Today – May 7, 2026
- Options Volatility and Implied Earnings Moves Today, May 07, 2026
- Gilead Shareholders Back Board, Pay Plans at 2026 Meeting
- Options Volatility and Implied Earnings Moves This Week, May 04 – May 07, 2026
- Gilead announces U.S. FDA accepted NDA submission for bictegravir, lenacapavir